Literature DB >> 21750560

Mutations galore in myeloproliferative neoplasms: would the real Spartacus please stand up?

A Tefferi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21750560     DOI： 10.1038/leu.2011.92

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly.

Authors:  Keita Kirito; Kenshi Suzuki; Koichi Miyamura; Masahiro Takeuchi; Hiroshi Handa; Shinichiro Okamoto; Brian Gadbaw; Kyosuke Yamauchi; Taro Amagasaki; Kazuo Ito; Masayuki Hino
Journal:  Int J Hematol       Date:  2017-09-27       Impact factor: 2.490

2.  Protein kinase Cɛ inhibition restores megakaryocytic differentiation of hematopoietic progenitors from primary myelofibrosis patients.

Authors:  E Masselli; C Carubbi; G Gobbi; P Mirandola; D Galli; S Martini; S Bonomini; M Crugnola; L Craviotto; F Aversa; M Vitale
Journal:  Leukemia       Date:  2015-06-19       Impact factor: 11.528

3.  Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway.

Authors:  Lakshmi Reddy Palam; Raghuveer Singh Mali; Baskar Ramdas; Sridhar Nonavinkere Srivatsan; Valeria Visconte; Ramon V Tiu; Bart Vanhaesebroeck; Axel Roers; Alexander Gerbaulet; Mingjiang Xu; Sarath Chandra Janga; Clifford M Takemoto; Sophie Paczesny; Reuben Kapur
Journal:  JCI Insight       Date:  2018-02-22

Review 4.  How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.

Authors:  Andreas Reiter; Claire Harrison
Journal:  Curr Hematol Malig Rep       Date:  2016-10       Impact factor: 3.952

Review 5.  TET proteins and 5-methylcytosine oxidation in hematological cancers.

Authors:  Myunggon Ko; Jungeun An; William A Pastor; Sergei B Koralov; Klaus Rajewsky; Anjana Rao
Journal:  Immunol Rev       Date:  2015-01       Impact factor: 12.988

6.  Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis.

Authors:  Keita Kirito; Shinichiro Okamoto; Kohshi Ohishi; Tetsuzo Tauchi; Hiroshi Handa; Shigeki Saito; Katsuto Takenaka; Kazuya Shimoda; Kenji Oritani; Koichi Akashi; Hikaru Okada; Taro Amagasaki; Kazuyuki Suzuki; Toshio Yonezu; Norio Komatsu
Journal:  Int J Hematol       Date:  2017-10-06       Impact factor: 2.490

7.  Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.

Authors:  Alfonso Quintás-Cardama; Omar Abdel-Wahab; Taghi Manshouri; Outi Kilpivaara; Jorge Cortes; Anne-Laure Roupie; Su-Jiang Zhang; David Harris; Zeev Estrov; Hagop Kantarjian; Ross L Levine; Srdan Verstovsek
Journal:  Blood       Date:  2013-06-19       Impact factor: 22.113

Review 8.  Myeloid malignancies: mutations, models and management.

Authors:  Anne Murati; Mandy Brecqueville; Raynier Devillier; Marie-Joelle Mozziconacci; Véronique Gelsi-Boyer; Daniel Birnbaum
Journal:  BMC Cancer       Date:  2012-07-23       Impact factor: 4.430

9.  Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia.

Authors:  E K Engle; D A C Fisher; C A Miller; M D McLellan; R S Fulton; D M Moore; R K Wilson; T J Ley; S T Oh
Journal:  Leukemia       Date:  2014-09-25       Impact factor: 11.528

Review 10.  Current and future treatment options for polycythemia vera.

Authors:  Martin Griesshammer; Heinz Gisslinger; Ruben Mesa
Journal:  Ann Hematol       Date:  2015-04-02       Impact factor: 3.673
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.